COVID-19 information for people living with asthma: A rapid review of publicly available information.
Ontology highlight
ABSTRACT:
SUBMITTER: McClatchey K
PROVIDER: S-EPMC7813501 | biostudies-literature | 2021 May
REPOSITORIES: biostudies-literature
Publications
COVID-19 information for people living with asthma: A rapid review of publicly available information.
McClatchey Kirstie K Jackson Tracy T Delaney Brigitte B Morgan Noelle N Pinnock Hilary H Chan Amy Hai Yan AHY
The journal of allergy and clinical immunology. In practice 20210118 5
Similar Datasets
Project description:The JRC COVID-19 In Vitro Diagnostic Devices and Test Methods Database, aimed to collect in a single place all publicly available information on performance of CE-marked in vitro diagnostic medical devices (IVDs) as well as in house laboratory-developed devices and related test methods for COVID-19, is here presented. The database, manually curated and regularly updated, has been developed as a follow-up to the Communication from the European Commission "Guidelines on in vitro diagnostic tests and their performance" of 15 April 2020 and is freely accessible at https://covid-19-diagnostics.jrc.ec.europa.eu/.
| S-EPMC7851715 | biostudies-literature
Project description: Not available
| S-EPMC11565261 | biostudies-literature
Project description:This systematic review summarizes the evidence on the earliest patients with COVID-19-HIV co-infection. We searched PubMed, Scopus, Web of Science, Embase, preprint databases, and Google Scholar from December 01, 2019, to June 1, 2020. From an initial 547 publications and 75 reports, 25 studies provided specific information on COVID-19 patients living with HIV. Studies described 252 patients, 80.9% were male, the mean age was 52.7 years, and 98% were on antiretroviral treatment (ART). Co-morbidities in addition to HIV and COVID-19 (multimorbidity) included hypertension (39.3%), obesity or hyperlipidemia (19.3%), chronic obstructive pulmonary disease (18.0%), and diabetes (17.2%). Two-thirds (66.5%) had mild to moderate symptoms, the most common being fever (74.0%) and cough (58.3%). Among patients who died, the majority (90.5%) were over 50 years old, male (85.7%), and had multimorbidity (64.3%). Our findings highlight the importance of identifying co-infections, addressing co-morbidities, and ensuring a secure supply of ART for PLHIV during the COVID-19 pandemic.
| S-EPMC7391049 | biostudies-literature
Project description:Many important questions remain regarding severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the viral pathogen responsible for COVID-19. These questions include the mechanisms explaining the high percentage of asymptomatic but highly infectious individuals, the wide variability in disease susceptibility, and the mechanisms of long-lasting debilitating effects. Bioinformatic analysis of four coronavirus datasets representing previous outbreaks (SARS-CoV-1 and MERS-CoV), as well as SARS-CoV-2, revealed evidence of diverse host factors that appear to be coopted to facilitate virus-induced suppression of interferon-induced innate immunity, promotion of viral replication and subversion and/or evasion of antiviral immune surveillance. These host factors merit further study given their postulated roles in COVID-19-induced loss of smell and brain, heart, vascular, lung, liver, and gut dysfunction.
| S-EPMC8480897 | biostudies-literature
Project description:BackgroundEffective disease self-management lowers asthma's burden of disease for both individual patients and health care systems. In principle, mobile health (mHealth) apps could enable effective asthma self-management interventions that improve a patient's quality of life while simultaneously reducing the overall treatment costs for health care systems. However, prior reviews in this field have found that mHealth apps for asthma lack clinical evaluation and are often not based on medical guidelines. Yet, beyond the missing evidence for clinical efficacy, little is known about the potential apps might have for improving asthma self-management.ObjectiveThe aim of this study was to assess the potential of publicly available and well-adopted mHealth apps for improving asthma self-management.MethodsThe Apple App store and Google Play store were systematically searched for asthma apps. In total, 523 apps were identified, of which 38 apps matched the selection criteria to be included in the review. Four requirements of app potential were investigated: app functions, potential to change behavior (by means of a behavior change technique taxonomy), potential to promote app use (by means of a gamification components taxonomy), and app quality (by means of the Mobile Application Rating Scale [MARS]).ResultsThe most commonly implemented functions in the 38 reviewed asthma apps were tracking (30/38, 79%) and information (26/38, 68%) functions, followed by assessment (20/38, 53%) and notification (18/38, 47%) functions. On average, the reviewed apps applied 7.12 of 26 available behavior change techniques (standard deviation [SD]=4.46) and 4.89 of 31 available gamification components (SD=4.21). Average app quality was acceptable (mean=3.17/5, SD=0.58), whereas subjective app quality lied between poor and acceptable (mean=2.65/5, SD=0.87). Additionally, the sum scores of all review frameworks were significantly correlated (lowest correlation: r36=.33, P=.04 between number of functions and gamification components; highest correlation: r36=.80, P<.001 between number of behavior change techniques and gamification components), which suggests that an app's potential tends to be consistent across review frameworks.ConclusionsSeveral apps were identified that performed consistently well across all applied review frameworks, thus indicating the potential mHealth apps offer for improving asthma self-management. However, many apps suffer from low quality. Therefore, app reviews should be considered as a decision support tool before deciding which app to integrate into a patient's asthma self-management. Furthermore, several research-practice gaps were identified that app developers should consider addressing in future asthma apps.
| S-EPMC5559650 | biostudies-literature
Project description: Not available
| S-EPMC9891348 | biostudies-literature
Project description:There is great concern about the impact of COVID-19 among the nearly 40 million people living with HIV (PLWH) worldwide. In this review, we surveyed current literature and found no evidence of higher prevalence of COVID-19 among PLWH but equivocal data on increased mortality and worse clinical outcomes. Having HIV does not confer protection against severe manifestations of COVID-19. Several studies looking at antiretroviral drugs against HIV to treat SARS-CoV-2 have shown no mortality benefit. Thus, there is no indication to change antiretroviral therapy (ART) regimens among virologically suppressed PLWH to prevent COVID-19. HIV care delivery has been adversely impacted in several countries during this pandemic but has created an opportunity for accelerating effective strategies like multi-month ART. Decentralizing HIV care in low-resource settings and incorporating telemedicine in high-resource settings will be critical in mitigating shocks to healthcare systems in the future.
| S-EPMC7560116 | biostudies-literature
Project description:The first case of COVID-19 was confirmed in Israel on February 21, 2020. Within approximately 30 days, the total number of confirmed cases climbed up to 1, 000, accompanied by a doubling period of less than 3 days. About one week later, after this number exceeded 4, 000 cases, and following some extreme lockdown measures taken by the Israeli government, the daily infection rate started a sharp decrease from the peak value of 1, 131 down to slightly more than 100 new confirmed cases on April 30. Motivated by this encouraging data, similar to the trends observed in many other countries, along with the growing economic pressures, the Israeli government has quickly lifted most of its emergency regulations. Throughout May, the daily number of new cases stayed at a very low level of 20-40 until at the end of May it started a steady increase, exceeding 1, 000 by the end of June and 2, 000 on July 22. As suggested by some experts and popular media, this disturbing trend may be even a part of a "second wave". This article attempts to analyze the data available on Israel at the end of July 2020, compared to three European countries (Greece, Italy, and Sweden), in order to understand the local dynamics of COVID-19, assess the effect of the implemented intervention measures, and discuss some plausible scenarios for the foreseeable future.
| S-EPMC7595440 | biostudies-literature
Project description:We describe a method to estimate individual risks of hospitalization and death attributable to non-household and household transmission of SARS-CoV-2 using available public data on confirmed-case incidence data along with estimates of the clinical fraction, timing of transmission, isolation adherence, secondary infection risks, contact rates, and case-hospitalization and case-fatality ratios. Using the method, we estimate that risks for a 90-day period at the median daily summertime U.S. county confirmed COVID-19 case incidence of 10.8 per 100,000 and pre-pandemic contact rates range from 0.4 to 8.9 per 100,000 for the four deciles of age between 20 and 60 years. The corresponding 90-day period risk of hospitalization ranges from 13.7 to 69.2 per 100,000. Assuming a non-household secondary infection risk of 4% and pre-pandemic contact rates, the share of transmissions attributable to household settings ranges from 73% to 78%. These estimates are sensitive to the parameter assumptions; nevertheless, they are comparable to the COVID-19 hospitalization and fatality rates observed over the time period. We conclude that individual risk of hospitalization and death from SARS-CoV-2 infection is calculable from publicly available data sources. Access to publicly reported infection incidence data by setting and other exposure characteristics along with setting specific estimates of secondary infection risk would allow for more precise individual risk estimation.
| S-EPMC7721133 | biostudies-literature
Project description:BackgroundThe COVID-19 pandemic has led to an increase in health information-seeking behavior (HISB) on the Internet.ObjectiveThis review aims to identify and synthesize the available evidence on health information-seeking behavior on the Internet during and after the COVID-19 pandemic.MethodsElectronic search of databases was conducted on PubMed, ScienceDirect, Scopus, and Taylor and Francis Online to identify relevant articles. Studies that examined health information-seeking behavior on the Internet during or after the COVID-19 pandemic were included. Data from the included studies were subjected to a thematic analysis.ResultsA total of 355 articles were identified in the initial database search. After screening, 15 articles were included in this review paper, with a population of 33,326. Search engines, social media, and news portals were the most commonly used information sources. The primary motivators for seeking health information online were curiosity, catching up with updated information, and paying attention to the COVID-19 transmission. Participants' satisfaction with the information obtained online was positive in most studies. The online query for all items related to COVID-19 and health increased during the pandemic. The most searched topics were symptoms of COVID-19, restrictions, current prevalence/spread of COVID-19, and preventive measures. Higher scores in digital health literacy (DHL) were associated with a well-established and effective health information-seeking behavior.ConclusionThe findings of this review provide insight into the patterns and trends of health information-seeking behavior on the Internet during and after the COVID-19 pandemic. The results suggest that search engines, social media, and news portals remain key sources of information during the pandemic. It also assessed the relationship between the DHL and the HISB and found that having a good DHL generally meant a good HISB.
| S-EPMC10449606 | biostudies-literature